Covetrus Stock Forecast, Price & News

Covetrus (NASDAQ:CVET) Frequently Asked Questions

Is Covetrus a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Covetrus in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Covetrus stock.
View analyst ratings for Covetrus or view top-rated stocks.

How has Covetrus' stock price been impacted by COVID-19 (Coronavirus)?

Covetrus' stock was trading at $9.04 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CVET stock has increased by 91.6% and is now trading at $17.32.
View which stocks have been most impacted by COVID-19.

When is Covetrus' next earnings date?

Covetrus is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Covetrus.

How were Covetrus' earnings last quarter?

Covetrus, Inc. (NASDAQ:CVET) posted its quarterly earnings data on Thursday, November, 4th. The company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.17 by $0.03. The firm had revenue of $1.16 billion for the quarter, compared to analysts' expectations of $1.16 billion. Covetrus had a negative net margin of 1.20% and a positive trailing twelve-month return on equity of 0.94%.
View Covetrus' earnings history.

What price target have analysts set for CVET?

5 equities research analysts have issued twelve-month target prices for Covetrus' stock. Their forecasts range from $19.00 to $38.00. On average, they anticipate Covetrus' share price to reach $28.60 in the next twelve months. This suggests a possible upside of 65.1% from the stock's current price.
View analysts' price targets for Covetrus or view top-rated stocks among Wall Street analysts.

Who are Covetrus' key executives?

Covetrus' management team includes the following people:

• Benjamin C. Wolin, President, Chief Executive Officer & Director (LinkedIn Profile)
• Matthew J. Foulston, Chief Financial Officer & Executive Vice President
• Steve Palmucci, Global Chief Information Officer
• Georgina Wraight, President-Global Technology Solutions & EVP
• Andrew B. Coxhead, Chief Accounting Officer, VP & Controller

What is Benjamin Wolin's approval rating as Covetrus' CEO?

25 employees have rated Covetrus CEO Benjamin Wolin on Glassdoor.com. Benjamin Wolin has an approval rating of 89% among Covetrus' employees.

Who are some of Covetrus' key competitors?

Some companies that are related to Covetrus include Rite Aid (RAD), PetMed Express (PETS), 111 (YI), MedAvail (MDVL), Progressive Care (RXMD), China Jo-Jo Drugstores (CJJD), HealthWarehouse.com (HEWA), Dougherty's Pharmacy (MYDP), China Dasheng Biotechnology (CDBT), Dragon Jade International (DGJI) and Health Sciences Group (HESG).
View all of CVET's competitors.

What other stocks do shareholders of Covetrus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Covetrus investors own include Pfizer (PFE), NVIDIA (NVDA), Advanced Micro Devices (AMD), AT&T (T), Activision Blizzard (ATVI), Boeing (BA), Chegg (CHGG), Enphase Energy (ENPH), Enterprise Products Partners (EPD) and Livongo Health (LVGO).

What is Covetrus' stock symbol?

Covetrus trades on the NASDAQ under the ticker symbol "CVET."

Who are Covetrus' major shareholders?

Covetrus' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Frontier Capital Management Co. LLC (1.57%), State of Alaska Department of Revenue (0.05%), Aries Wealth Management (0.03%) and Spire Wealth Management (0.00%). Company insiders that own Covetrus stock include Anthony C Jr Providenti, Benjamin Wolin, David Stuart Hinton, Dustin Finer, Edward Mcnamara, Georgina Wraight, Herbert Virgin, Laura J Phillips, Michael Ellis and Timothy Ludlow.
View institutional ownership trends for Covetrus.

Which major investors are selling Covetrus stock?

CVET stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have sold Covetrus company stock in the last year include Benjamin Wolin, Dustin Finer, Edward Mcnamara, Herbert Virgin, Laura J Phillips, Michael Ellis, and Timothy Ludlow.
View insider buying and selling activity for Covetrus or view top insider-selling stocks.

Which major investors are buying Covetrus stock?

CVET stock was bought by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Aries Wealth Management, and Spire Wealth Management.
View insider buying and selling activity for Covetrus or or view top insider-buying stocks.

How do I buy shares of Covetrus?

Shares of CVET can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Covetrus' stock price today?

One share of CVET stock can currently be purchased for approximately $17.32.

How much money does Covetrus make?

Covetrus has a market capitalization of $2.39 billion and generates $4.34 billion in revenue each year. The company earns $-19 million in net income (profit) each year or ($0.41) on an earnings per share basis.

How many employees does Covetrus have?

Covetrus employs 5,657 workers across the globe.

What is Covetrus' official website?

The official website for Covetrus is www.henryscheinvet.com.

Where are Covetrus' headquarters?

Covetrus is headquartered at 7 CUSTOM HOUSE STREET, PORTLAND ME, 04101.

How can I contact Covetrus?

Covetrus' mailing address is 7 CUSTOM HOUSE STREET, PORTLAND ME, 04101. The company can be reached via phone at (888) 280-2221 or via email at [email protected].